202 related articles for article (PubMed ID: 16643621)
1. Peroxisome proliferator-activated receptor gamma is frequently underexpressed in renal cell carcinoma.
Yuan J; Takahashi A; Masumori N; Itoh N; Tsukamoto T
Int J Urol; 2006 Mar; 13(3):265-70. PubMed ID: 16643621
[TBL] [Abstract][Full Text] [Related]
2. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
[TBL] [Abstract][Full Text] [Related]
3. Ligands for peroxisome proliferator-activated receptor gamma have potent antitumor effect against human renal cell carcinoma.
Yuan J; Takahashi A; Masumori N; Uchida K; Hisasue S; Kitamura H; Itoh N; Tsukamoto T
Urology; 2005 Mar; 65(3):594-9. PubMed ID: 15780399
[TBL] [Abstract][Full Text] [Related]
4. Significance of Fas expression alteration during tumor progression of renal cell carcinoma.
Sejima T; Miyagawa I
Int J Urol; 2006 Mar; 13(3):257-64. PubMed ID: 16643620
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor gamma and growth inhibition by its ligands in uterine endometrial carcinoma.
Ota K; Ito K; Suzuki T; Saito S; Tamura M; Hayashi S; Okamura K; Sasano H; Yaegashi N
Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4200-8. PubMed ID: 16857792
[TBL] [Abstract][Full Text] [Related]
6. The expression of prostate stem cell antigen in human clear cell renal cell carcinoma: a quantitative reverse transcriptase-polymerase chain reaction analysis.
Elsamman EM; Fukumori T; Tanimoto S; Nakanishi R; Takahashi M; Toida K; Kanayama HO
BJU Int; 2006 Sep; 98(3):668-73. PubMed ID: 16925770
[TBL] [Abstract][Full Text] [Related]
7. Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma.
Suyama T; Furuya M; Nishiyama M; Kasuya Y; Kimura S; Ichikawa T; Ueda T; Nikaido T; Ito H; Ishikura H
Cancer; 2005 Jan; 103(2):258-67. PubMed ID: 15578685
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of vascular endothelial growth factor in renal cell carcinoma cells by glucocorticoids.
Iwai A; Fujii Y; Kawakami S; Takazawa R; Kageyama Y; Yoshida MA; Kihara K
Mol Cell Endocrinol; 2004 Oct; 226(1-2):11-7. PubMed ID: 15489000
[TBL] [Abstract][Full Text] [Related]
9. Detection of transcript for brain-type fatty Acid-binding protein in tumor and urine of patients with renal cell carcinoma.
Teratani T; Domoto T; Kuriki K; Kageyama T; Takayama T; Ishikawa A; Ozono S; Nozawa R
Urology; 2007 Feb; 69(2):236-40. PubMed ID: 17320655
[TBL] [Abstract][Full Text] [Related]
10. High-grade clear cell renal cell carcinoma has a higher angiogenic activity than low-grade renal cell carcinoma based on histomorphological quantification and qRT-PCR mRNA expression profile.
Baldewijns MM; Thijssen VL; Van den Eynden GG; Van Laere SJ; Bluekens AM; Roskams T; van Poppel H; De Bruïne AP; Griffioen AW; Vermeulen PB
Br J Cancer; 2007 Jun; 96(12):1888-95. PubMed ID: 17505508
[TBL] [Abstract][Full Text] [Related]
11. Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor.
Shoji S; Tang XY; Umemura S; Itoh J; Takekoshi S; Shima M; Usui Y; Nagata Y; Uchida T; Osamura RY; Terachi T
Eur Urol; 2009 Feb; 55(2):441-9. PubMed ID: 18395325
[TBL] [Abstract][Full Text] [Related]
12. Characterization and gene expression analysis of novel matched primary and metastatic renal cell carcinoma cell lines.
Ohno Y; Izumi M; Tachibana M; Kawamura T; Yoshioka K; Aoyagi T; Ohori M; Namiki K; Sakamoto N; Nakagami Y; Hatano T; Akimoto S; Nishimura T
Oncol Rep; 2008 Sep; 20(3):501-9. PubMed ID: 18695898
[TBL] [Abstract][Full Text] [Related]
13. mRNA expression profiles of methylated APAF-1 and DAPK-1 tumor suppressor genes uncover clear cell renal cell carcinomas with aggressive phenotype.
Christoph F; Hinz S; Kempkensteffen C; Schostak M; Schrader M; Miller K
J Urol; 2007 Dec; 178(6):2655-9. PubMed ID: 17945286
[TBL] [Abstract][Full Text] [Related]
14. 5-Lipoxygenase inhibitors attenuate growth of human renal cell carcinoma and induce apoptosis through arachidonic acid pathway.
Matsuyama M; Yoshimura R; Mitsuhashi M; Tsuchida K; Takemoto Y; Kawahito Y; Sano H; Nakatani T
Oncol Rep; 2005 Jul; 14(1):73-9. PubMed ID: 15944770
[TBL] [Abstract][Full Text] [Related]
15. Increased RANKL expression is related to tumour migration and metastasis of renal cell carcinomas.
Mikami S; Katsube K; Oya M; Ishida M; Kosaka T; Mizuno R; Mochizuki S; Ikeda T; Mukai M; Okada Y
J Pathol; 2009 Aug; 218(4):530-9. PubMed ID: 19455604
[TBL] [Abstract][Full Text] [Related]
16. Genomic profiling identifies alterations in TGFbeta signaling through loss of TGFbeta receptor expression in human renal cell carcinogenesis and progression.
Copland JA; Luxon BA; Ajani L; Maity T; Campagnaro E; Guo H; LeGrand SN; Tamboli P; Wood CG
Oncogene; 2003 Sep; 22(39):8053-62. PubMed ID: 12970754
[TBL] [Abstract][Full Text] [Related]
17. Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas.
Cheung C; Vesey D; Cotterill A; Douglas M; Gobe G; Nicol D; Johnson D
Int J Urol; 2005 Jan; 12(1):17-28. PubMed ID: 15661050
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of Jab1 in hepatocellular carcinoma and its inhibition by peroxisome proliferator-activated receptor{gamma} ligands in vitro and in vivo.
Hsu MC; Huang CC; Chang HC; Hu TH; Hung WC
Clin Cancer Res; 2008 Jul; 14(13):4045-52. PubMed ID: 18593980
[TBL] [Abstract][Full Text] [Related]
19. Frequent loss of SFRP1 expression in multiple human solid tumours: association with aberrant promoter methylation in renal cell carcinoma.
Dahl E; Wiesmann F; Woenckhaus M; Stoehr R; Wild PJ; Veeck J; Knüchel R; Klopocki E; Sauter G; Simon R; Wieland WF; Walter B; Denzinger S; Hartmann A; Hammerschmied CG
Oncogene; 2007 Aug; 26(38):5680-91. PubMed ID: 17353908
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of full-length telomerase reverse transcriptase mRNA and telomerase activity between normal and malignant renal tissues.
Fan Y; Liu Z; Fang X; Ge Z; Ge N; Jia Y; Sun P; Lou F; Björkholm M; Gruber A; Ekman P; Xu D
Clin Cancer Res; 2005 Jun; 11(12):4331-7. PubMed ID: 15958614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]